Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy

NCT03610360 is registered in ClinicalTrials.gov with Amphera BV as lead sponsor.

NCT NCT03610360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
Lead sponsor
Amphera BV
Phase
Phase 2/3
Overall status
Completed
Start date
June 21, 2018
Completion date
June 30, 2022
Enrollment
176 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma